Results for ticlopidin translation from Danish to English

ticlopidin
ticlopidine

ticlopidin, prasugrel) (se pkt.
prasugrel) (see

ticlopidin, der er anden medicin mod blodpropper
ticlopidine, other antiplatelet agent

acetylsalicylsyre eller acetylsalicylsyre plus clopidogrel eller ticlopidin.
acetylsalicylic acid (also known as aspirin) or acetylsalicylic acid plus clopidogrel or ticlopidine.

ticlopidin eller clopidogrel, hovedsagelig til behandling af hjertesygdomme eller slagtilfælde
ticlopidine or clopidogrel, mainly used in the treatment of heart disease or stroke;

acetylsalicylsyre (også kaldet aspirin) eller acetylsalicylsyre plus clopidogrel eller ticlopidin.
acetylsalicylic acid (also known as aspirin) or acetylsalicylic acid plus clopidogrel or ticlopidine.

samtidig brug af desirudin med trombolytika og ticlopidin er endnu ikke blevet undersøgt i denne patientpopulation.
the concomitant use of desirudin with thrombolytics and ticlopidine has not been investigated in this patient population.

henholdsvis 5 mg eller 10 mg administreret sammen med enten acetylsalicylsyre eller acetylsalicylsyre plus clopidogrel eller ticlopidin
5 mg or 10 mg respectively, co- administered with either asa or asa plus clopidogrel or ticlopidine

den skal tages enten sammen med aspirin eller sammen med aspirin og clopidogrel eller aspirin og ticlopidin.
it should be taken either in combination with aspirin or together with aspirin and clopidogrel or aspirin and ticlopidine.

samtidig behandling med-anti-blodplade stoffer udover acetylsalicylsyre, så som ticlopidin eller clopidogrel,
concomitant treatment with coumarin derivatives (vitamin k antagonists) and drugs that affect platelet function may also increase the risk of bleeding.

virkningen af og sikkerheden ved xarelto er undersøgt i kombination med de antitrombotiske stoffer acetylsalicylsyre og clopidogrel/ticlopidin.
efficacy and safety of xarelto has been investigated in combination with the antiplatelet agents aspirin and clopidogrel/ticlopidine.

anden trombocythæmmende medicin (acetylsalicylsyre, dipyramidol, sulfinpyrazon, ticlopidin eller clopidogrel) samt nsaids bør ge
if ed

carbamazepin eller oxcarbazepin, medicin der anvendes mod bestemte former for epilepsi ticlopidin, der er en anden blodfortyndende medicin mod blodpropper.
carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy, ticlopidine, other antiplatelet agent.

placeboarmen var tilsvarende (acetylsalicylsyre 99,7 %, clopidogrel 95,9 %, ticlopidin 2,6 %).
the placebo arm was comparable (aspirin 99.7 %, clopidogrel 95.9 %, ticlopidin 2.6 %).

anden trombocythæmmende medicin (acetylsalicylsyre, dipyramidol, sulfinpyrazon, ticlopidin eller clopidogrel) samt nsaids bør anvendes med forsigtighed.
other antiplatelet medicinal products (acetylsalicylic acid, dipyridamole, sulfinpyrazone, ticlopidine or clopidogrel), and nsaids should be used with caution.

interaktionsundersøgelser har været udført med blodplade-inhibitorer, herunder acetylsalicylsyre, ticlopidin, clopidogrel, abciximab, eptifibatid eller tirofiban.
interaction studies have been conducted with platelet inhibitors, including acetylsalicylic acid, ticlopidine, clopidogrel, abciximab, eptifibatide, or tirofiban.

4. 5 anden trombocythæmmende medicin (acetylsalicylsyre, dipyramidol, sulfinpyrazon, ticlopidin eller clopidogrel) samt nsaids bør anvendes med forsigtighed.
during treatment of vte, concomitant therapy with vitamin k antagonist should be administered in accordance with the information of section 4.5.

efter et akut koronarsyndrom bør patienter i behandling med xarelto og asa eller xarelto og asa plus clopidogrel/ticlopidin kun få samtidig behandling med nsaid’er, hvis fordelen opvejer blødningsrisikoen.
after an acute coronary syndrome patients on treatment with xarelto and asa or xarelto and asa plus clopidogrel/ticlopidine should only receive concomitant treatment with nsaids if the benefit outweighs the bleeding risk.

blandt patienterne, som fik dobbelt antitrombotisk behandling, fik 98,8 % clopidogrel, 0,9 % fik ticlopidin og 0,3 % fik prasugrel.
among patients receiving dual anti-platelets therapy 98.8% received clopidogrel, 0.9 % received ticlopidine and 0.3 % received prasugrel.

i armen med eptifibatid i undersøgelsen fik næsten alle patienter acetylsalicylsyre (99,7 %), og 98,1 % fik thienopyridin (clopidogrel hos 95,4 % og ticlopidin hos 2,7 %).
in the eptifibatide arm of the trial, virtually all patients received aspirin (99.7 %), and 98.1 % received a thienopyridine, (clopidogrel in 95.4 % and ticlopidine in 2.7 %).